A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. That said, here are two low-volatility stocks providing safe-and-steady growth and one that may not deliver the returns you need.
One Stock to Sell:
Excelerate Energy (EE)
Rolling One-Year Beta: -0.17
Operating specialized vessels that can deliver up to 1.2 billion cubic feet of natural gas per day, Excelerate Energy (NYSE: EE) provides liquified natural gas regasification services using floating vessels that convert LNG back into natural gas.
Why Do We Think Twice About EE?
- Modest revenue base of $1.47 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- Gross margin of 29.9% reflects its high production costs and unfavorable asset base
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 5.5% for the last five years
At $32.65 per share, Excelerate Energy trades at 16.4x forward P/E. Read our free research report to see why you should think twice about including EE in your portfolio.
Two Stocks to Watch:
Vertex Pharmaceuticals (VRTX)
Rolling One-Year Beta: 0.39
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Why Does VRTX Catch Our Eye?
- Solid 13.5% annual revenue growth over the last five years indicates its offerings solve complex business issues
- Adjusted operating margin expanded by 38.6 percentage points over the last two years as it scaled and became more efficient
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
Vertex Pharmaceuticals’s stock price of $508.15 implies a valuation ratio of 39.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
Cigna (CI)
Rolling One-Year Beta: 0.09
With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE: CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans.
Why Are We Positive on CI?
- Solid 13.8% annual revenue growth over the last two years indicates its offerings solve complex business issues
- Unparalleled scale of $282.1 billion in revenue enables it to spread administrative costs across a larger membership base
- Earnings per share grew by 12% annually over the last five years, comfortably beating the peer group average
Cigna is trading at $269.90 per share, or 8.4x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
